EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Functionalized Magnetic Fe3O4 Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy

Julia Nowak-Jary, Artur Płóciennik, Beata Machnicka iD

International Journal of Molecular Sciences · 22.08.2024 · 25 (16) · 9098

DOI: 10.3390/ijms25169098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.08.2024. Verfasst von Julia Nowak-Jary und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Institute of Biological Sciences, University of Zielona Gora, 65-516 Zielona Gora, Poland. Hauptthemen laut MEDLINE: Methotrexate, Ovarian Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Magnetic Fe3O4 nanoparticles (MNPs) functionalized with (3-aminopropylo)trietoksysilan (APTES) or N-carboxymethylchitosan (CMC) were proposed as nanocarriers of methotrexate (MTX) to target ovarian cancer cell lines. The successful functionalization of the obtained nanostructures was confirmed by FT-IR spectroscopy. The nanoparticles were characterized by transmission electron spectroscopy (TEM) and dynamic light scattering (DLS) techniques. Their potential zeta, magnetization, and hyperthermic properties were also explored. MTX was conjugated with the nanocarriers by ionic bonds or by amide bonds. The drug release kinetics were examined at different pH and temperatures. The MTT assay showed no toxicity of the MNPs[APTES] and MNPs[CMC]. Finally, the cytotoxicity of the nanostructures with MTX attached towards the ovarian cancer cells was measured. The sensitivity and resistance to methotrexate was determined in simplistic 2D and spheroid 3D conditions. The cytotoxicity tests of the tested nanostructures showed similar values for inhibiting the proliferation of ovarian cancer cells as methotrexate in its free form. Conjugating MTX with nanoparticles allows the drug to be directed to the target site using an external magnetic field, reducing overall toxicity. Combining this approach with hyperthermia could enhance the therapeutic effect in vivo compared to free MTX, though further research on advanced 3D models is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateOvarian NeoplasmsFemaleHumansCell Line, TumorMagnetite NanoparticlesDrug CarriersDrug Delivery SystemsMagnetic Iron Oxide NanoparticlesDrug LiberationAntimetabolites, AntineoplasticCell Survival

Stichwörter der Autor:innen

cytotoxicitymagnetic iron oxide nanoparticlesmethotrexateovarian cancer

Substanzen

MethotrexateMagnetite NanoparticlesDrug CarriersAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Biotechnology, Institute of Biological Sciences, University of Zielona Gora, 65-516 Zielona Gora, Poland.
  • Institute of Experimental Biology, University of Poznan, 61-614 Poznan, Poland.

ORCID-Profile: Beata Machnicka

Zitieren

APA

Nowak-Jary, J., Płóciennik, A., & Machnicka, B. (2024). Functionalized Magnetic Fe3O4 Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy. International Journal of Molecular Sciences, 25(16), 9098. https://doi.org/10.3390/ijms25169098

Vancouver

Nowak-Jary J, Płóciennik A, Machnicka B. Functionalized Magnetic Fe3O4 Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy. International Journal of Molecular Sciences. 2024;25(16):9098. doi:10.3390/ijms25169098

BibTeX
@article{NowakJary2024,
  author = {Nowak-Jary, Julia and Płóciennik, Artur and Machnicka, Beata},
  title = {Functionalized Magnetic Fe3O4 Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {16},
  pages = {9098},
  doi = {10.3390/ijms25169098}
}
Kostenlos starten →